Se connecter

Bibliographies thématiques / Tumor Residual / Thèses

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Tumor Residual.

Thèses sur le sujet « Tumor Residual »

Auteur : Grafiati

Publié le 9 mars 2023

Mis à jour le 31 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 27 meilleures thèses pour votre recherche sur le sujet « Tumor Residual ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les thèses sur diverses disciplines et organisez correctement votre bibliographie.

1

Takeda, Kazuna. "MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy." Kyoto University, 2012. http://hdl.handle.net/2433/157449.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Oliveira, Marcelo de Lima. "Ultrassonografia durante cirurgia para metástase cerebral: influência no índice de Karnofsky e volume do tumor residual." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/5/5138/tde-09082016-151729/.

Texte intégral

Résumé :

Introdução: Os principais objetivos do tratamento das metástases cerebrais (MC) são no auxílio do controle da doença no encéfalo e a melhora da qualidade de vida dos pacientes. A cirurgia convencional tem um importante papel no tratamento das MCs e os métodos de monitoração intraoperatória podem auxiliar na obtenção de resultados cirúrgicos melhores. Objetivos: Avaliar a influência da ultrassonografia encefálica durante cirurgia para ressecção de MC no índice de Karnofsky e no grau de ressecção do tumor. Métodos: Neste estudo prospectivo controlado e não randomizado, doentes com indicação de t

Styles APA, Harvard, Vancouver, ISO, etc.

3

Costa-Gurgel, Maria Salete 1956. "Aspectos histologicos relacionados com a persistencia de tumor residual apos conização em pacientes com carcinoma microinvasivo do colo uterino." [s.n.], 1994. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310012.

Texte intégral

Résumé :

Orientador: Aloisio José Bedone<br>Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas<br>Made available in DSpace on 2018-07-19T18:28:24Z (GMT). No. of bitstreams: 1 Costa-Gurgel_MariaSalete_M.pdf: 1948436 bytes, checksum: 9652cc74f1c4e8abd0a8359398a304a0 (MD5) Previous issue date: 1994<br>Resumo: O tratamento do carcinoma microinvasivo do colo uterino é bastante controverso, sendo abordado diferentemente nos diversos Serviços. A histerectomia, acompanhada ou não de procedimentos mais radicais, é realizada na quase totalidade dos casos. Mais recentement

Styles APA, Harvard, Vancouver, ISO, etc.

4

Marighetti, P. "RESIDUAL DORMANT CANCER STEM CELL FOCI ARE RESPONSIBLE FOR TUMOR RELAPSE AFTER ANGIOGENIC METRONOMIC THERAPY IN HEPATOCELLULAR CARCINOMA XENOGRAFTS." Doctoral thesis, Università degli Studi di Milano, 2012. http://hdl.handle.net/2434/169919.

Texte intégral

Résumé :

Hepatocellular carcinoma (HCC) is the fifth most common solid tumor and the third leading cause of cancer-related death. Current available chemotherapeutic options are not curative due in part to their resistance to conventional therapies. We have generated orthotopic HCC mouse models in immunodeficient NOD/SCID/IL2rγ null mice by injection of AFP- and/or luciferase-expressing HCC cell lines and primary cells from patients, where tumor growth and spread can be accurately monitored in a non-invasive way. Low dose metronomic administration of cyclophosphamide (LDM-CTX) causes in this model comp

Styles APA, Harvard, Vancouver, ISO, etc.

5

Vu-Han, Tu-Lan [Verfasser], and Reinhard [Akademischer Betreuer] Schneppenheim. "Identifying Molecular Markers for the Sensitive Detection of Residual Atypical Teratoid Rhaboid-Tumor Cells / Tu-Lan Vu-Han. Betreuer: Reinhard Schneppenheim." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2016. http://d-nb.info/1082347604/34.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Vu-Han, Tu-Lan Verfasser], and Reinhard [Akademischer Betreuer] [Schneppenheim. "Identifying Molecular Markers for the Sensitive Detection of Residual Atypical Teratoid Rhaboid-Tumor Cells / Tu-Lan Vu-Han. Betreuer: Reinhard Schneppenheim." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2016. http://nbn-resolving.de/urn:nbn:de:gbv:18-77221.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Morales, Murillo Serafín. "Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0cm.) tras Quimioterapia neoadyuvante." Doctoral thesis, Universitat de Lleida, 2015. http://hdl.handle.net/10803/401677.

Texte intégral

Résumé :

La identificació de marcadors moleculars en el tumor residual després de quimioteràpia neoadjuvant ( QTN ) en Càncer de Mama permet una millor caracterització pronostica . S'han seleccionat un total de 256 pacients amb QTN entre 1996 i 2011 , amb tumor residual ( > 1 cm ) . S'ha realitzat una matriu matricial de teixits i estudi inmunohistoquimic de l'expressió de 29 marcadors moleculars . L'anàlisi s'ha realitzat sobre l'aparició de metàstasi i la supervivència lliure de progressió a distància . El model multivariant ( mètode stepwise ) obté una signatura molecular amb sis marcadors de mal pr

Styles APA, Harvard, Vancouver, ISO, etc.

8

PEIRETTI, MICHELE. "Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. single institution experience." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2010. http://hdl.handle.net/10281/8049.

Texte intégral

Résumé :

Objective. The objective of the present study was to determinate the impact of maximal cytoreductive surgery on progression free survival, overall survival rates and morbidity, in patients with advanced epithelial ovarian or fallopian tube cancer (stage IIIC-IV) treated in a referral cancer center. Methods. After obtaining Institutional Review Board approval, we reviewed all medical records of patients with stage IIIC–IV epithelial ovarian cancer who were managed at our institution between January 2001 and December 2008. Individual records were reviewed and the following information collected

Styles APA, Harvard, Vancouver, ISO, etc.

9

Milano, Jeronimo Buzetti. "Estudo das alterações em exames de ressonância magnética de pacientes em pós-operatório imediato de ressecção de tumores hipofisários por via transesfenoidal." Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5138/tde-22062010-125138/.

Texte intégral

Résumé :

Exames pós-operatórios de cirurgias intracranianas são difíceis de serem interpretados por apresentarem alterações morfológicas que simulam situações patológicas, como edema e tumores residuais. Com o advento de métodos de ressonância intraoperatória essa interpretação ganhou maior importância, pelo risco de re-intervenções desnecessárias. O presente estudo objetivou estabelecer as características de exames pós-operatórios normais após remoção de tumores hipofisários pela via transesfenoidal endonasal, bem como estabelecer parâmetros de remoção tumoral radical para otimização de exames intraop

Styles APA, Harvard, Vancouver, ISO, etc.

10

Rick, Oliver. "Therapieoptimierungsverfahren bei Patienten mit rezidivierten oder progredienten Keimzelltumoren." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2004. http://dx.doi.org/10.18452/13921.

Texte intégral

Résumé :

Patienten mit metastasierten Keimzelltumoren, die einen Progress oder ein Rezidiv ihrer Erkrankung nach einer cisplatinhaltigen Vortherapie erleiden, haben eine schlechte Prognose. Unter Verwendung einer erneuten konventionellen Chemotherapie können maximal 15-30% dieser Patienten geheilt werden, so dass die Mehrzahl der Patienten an ihrer Erkrankung verstirbt. Aus diesem Grund ist die Optimierung der therapeutischen Möglichkeiten ein wesentliches Ziel. Unsere Daten zeigen, dass die Hochdosischemotherapie (HDCT) eine wesentliche therapeutische Verbesserung darstellt und mittels dieser Therapie

Styles APA, Harvard, Vancouver, ISO, etc.

11

Mopin, Alexia. "Développement d’un modèle murin syngénique et immun de leucémie aiguë myéloïde et de maladie résiduelle mesurable surexprimant ou non le gène Wilms Tumor 1." Thesis, Lille 2, 2018. http://www.theses.fr/2018LIL2S035/document.

Texte intégral

Résumé :

Les leucémies aiguës myéloïdes (LAM) sont des hémopathies malignes hétérogènes déclenchées, dans la plupart des cas, par des anomalies génétiques (mutations, translocations ou inversions). Elles se caractérisent par un blocage de la différenciation de certains progéniteurs ou précurseurs hématopoïétiques (blastes) et leur prolifération clonale incontrôlée provoquant leur accumulation dans la moelle osseuse. Le traitement actuel de ces patients repose essentiellement sur l’utilisation d’agents de chimiothérapie (cytarabine associée à une anthracycline) permettant d’éliminer les cellules leucémi

Styles APA, Harvard, Vancouver, ISO, etc.

12

Kuniyoshi, Renata Kelly. "Estudo do perfilamento gênico tumoral e de marcadores de doença residual mínima (CK19 e c-ErbB-2) através de RT-PCR quantitativo na fração mononuclear do sangue periférico em pacientes com câncer de mama durante o tratamento." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/5/5167/tde-12022014-160250/.

Texte intégral

Résumé :

INTRODUÇÃO: De acordo com a estimativa de 2012 do INCA, eram esperados 52.680 novos casos de câncer de mama no Brasil, com um risco estimado de 52 casos a cada 100 mil mulheres. Estes dados mostram a necessidade da identificação de biomarcadores efetivos para rastreamento precoce e seguimento destas mulheres durante seu tratamento. Neste trabalho, para a avaliação de potenciais biomarcadores desta doença, foi idealizado um modelo laboratorial específico que avalie tanto a capacidade de um dado biomarcador rastrear um tumor inicial de mama, bem como testar o seu potencial valor para o seguiment

Styles APA, Harvard, Vancouver, ISO, etc.

13

Linhares, José Clemente. "Medida de qualidade de tumor residual como método preditivo da sobrevida após quimioterapia neoadjuvante no tratamento do câncer de mama : validação de uma nova metodologia / José Clemente Linhares ; coordenador, Luiz Carlos Von Bathen ; orientador, Flávio Daniel Saavedra Tomasich." reponame:Biblioteca Digital de Teses e Dissertações da PUC_PR, 2011. http://www.biblioteca.pucpr.br/tede/tde_busca/arquivo.php?codArquivo=2431.

Texte intégral

Résumé :

Dissertação (mestrado) - Pontifícia Universidade Católica do Paraná, Curitiba, 2011<br>Bibliografia: f. 39-44<br>Introdução: Apesar dos significantes avanços no conhecimento no uso da quimioterapia primária ou neoadjuvante no tratamento do câncer da mama, ainda não se estabeleceu um método adequado para a quantificação da doença residual após o tratamento e a sua re<br>Introduction: Although we have had significant improvement in knowledge on the use of primary chemotherapy in breast cancer treatment, to the moment there is not an adequate method to evaluate the residual tumor burden after the

Styles APA, Harvard, Vancouver, ISO, etc.

14

Volpari, Tatiana. "Residual breast cancer metabolic phenotype after docetaxel treatment." Thesis, University of Birmingham, 2016. http://etheses.bham.ac.uk//id/eprint/6710/.

Texte intégral

Résumé :

Despite improvements in early diagnosis and prevention, late stage breast cancer is often incurable due to metastasis, tumour relapse, resistance and incomplete response to treatments. Metabolic reprogramming has been recognised as a critical element for cancer cells to grow under hostile conditions and this is likely to contribute towards resistance against chemotherapeutics. This thesis therefore aimed at deciphering the metabolic phenotype of residual breast cancer which survived docetaxel treatment, in vitro and in vivo, quantifying polar metabolite levels and conducting pathway tracing an

Styles APA, Harvard, Vancouver, ISO, etc.

15

Dionne, Sara O. "Tumor-derived peptides modified at HLA-A*0201 binding residues elicit cytotoxic T lymphocyte responses." Diss., The University of Arizona, 2002. http://hdl.handle.net/10150/280126.

Texte intégral

Résumé :

The immunotherapy of cancer aims to activate both the humoral and cellular arms of the immune system to generate a specific and effective anti-tumor response. Tumor cells express self-antigens which masks these cells from recognition by the immune system. Tumor cells display antigen in the context of Human Leukocyte Antigen (HLA) molecules presented on the cell surface. Cytotoxic T lymphocyte (CTL) recognition of antigenic peptide/HLA complexes results in destruction of the target cell. CTL are educated to discriminate between foreign and self-antigens, however tumor cells frequently express s

Styles APA, Harvard, Vancouver, ISO, etc.

16

Hakenberg, Oliver W., P. Franke, Michael Fröhner, Andreas Manseck, and Manfred Wirth. "The Value of Conventional Urine Cytology in the Diagnosis of Residual Tumour after Transurethral Resection of Bladder Carcinomas." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-135153.

Texte intégral

Résumé :

Background: Transurethral resection leads to characteristic histological changes of tissue repair (’TUR cystitis‘), which also cause non-specific cytological changes. The aim of this study was to investigate the diagnostic sensitivity and specificity of conventional exfoliative urinary cytology in diagnosing residual urothelial carcinoma after differential transurethral resection. Patients and Methods: 417 urinary cytology specimens of all 374 patients undergoing primary (n = 326) or secondary (n = 91) transurethral resection of urothelial carcinoma of the bladder at our institution between Ju

Styles APA, Harvard, Vancouver, ISO, etc.

17

Hakenberg, Oliver W., P. Franke, Michael Fröhner, Andreas Manseck, and Manfred Wirth. "The Value of Conventional Urine Cytology in the Diagnosis of Residual Tumour after Transurethral Resection of Bladder Carcinomas." Karger, 2000. https://tud.qucosa.de/id/qucosa%3A27624.

Texte intégral

Résumé :

Background: Transurethral resection leads to characteristic histological changes of tissue repair (’TUR cystitis‘), which also cause non-specific cytological changes. The aim of this study was to investigate the diagnostic sensitivity and specificity of conventional exfoliative urinary cytology in diagnosing residual urothelial carcinoma after differential transurethral resection. Patients and Methods: 417 urinary cytology specimens of all 374 patients undergoing primary (n = 326) or secondary (n = 91) transurethral resection of urothelial carcinoma of the bladder at our institution between Ju

Styles APA, Harvard, Vancouver, ISO, etc.

18

Richter, Daniel [Verfasser], Marco [Akademischer Betreuer] Durante, and Gerhard [Akademischer Betreuer] Kraft. "Treatment planning for tumors with residual motion in scanned ion beam therapy / Daniel Richter. Betreuer: Marco Durante ; Gerhard Kraft." Darmstadt : Universitäts- und Landesbibliothek Darmstadt, 2012. http://d-nb.info/1106117255/34.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

19

Dang, Raymond K. B. "Molecular detection of minimal residual disease in breast cancer and leukaemias using p53 tumour suppressor gene mutations as markers." Thesis, University of Edinburgh, 2000. http://hdl.handle.net/1842/22132.

Texte intégral

Résumé :

The use of peripheral blood progenitor cell (PBPC) transplantation is an important advance in the treatment of breast cancer and acute leukaemias, and these conditions are among the commonest indications for this procedure. Inevitably, there is concern that malignant cells may contaminate progenitor cell harvests and be re-infused during transplantation and cause disease relapse. Various methods are available for the detection of such minimal residual disease (MRD), and the key aim of this project was to evaluate the feasibility of using a tumour-specific marker, namely mutations within the p5

Styles APA, Harvard, Vancouver, ISO, etc.

20

Araujo, Robyn Patrice. "Mathematical modelling of mechanical stresses and vascular collapse in solid tumours." Thesis, Queensland University of Technology, 2003. https://eprints.qut.edu.au/37156/6/37156_Digitised_Thesis.pdf.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Nakamura, Kenichi. "Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A)." Kyoto University, 2016. http://hdl.handle.net/2433/217718.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Trilla, Herrera Enrique. "Estudio de factores pronósticos predictivos de la presencia de fibronecrosis en las masas residuales postquimioterapia en tumores de extirpe germinal." Doctoral thesis, Universitat de Barcelona, 2004. http://hdl.handle.net/10803/1223.

Texte intégral

Résumé :

HIPÓTESIS Y OBJETIVOS: <br/><br/>La presencia de masas residuales postquimioterapia es una circunstancia relativamente frecuente (30-60%) en pacientes afectos de tumores germinales testiculares (TGT) metastásicos tras la finalización de la quimioterapia de inducción y en ausencia de elevación de marcadores tumorales. La resección quirúrgica constituye el tratamiento comúnmente aceptado en estos casos y en especial en los TGT no seminomatosos. La histología de dichas masas revelará hasta en un 40% la presencia de fibronecrosis, teratoma maduro en un 40% y tumor germinal viable en el 20% restant

Styles APA, Harvard, Vancouver, ISO, etc.

23

Hamy, Anne-Sophie. "Identification of Factors Predicting Sensitivity or Resistance to Neoadjuvant Chemotherapy in Breast Cancer Neoadjuvant treatment : the future of patients with breast cancer Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an “option” but an ethical obligation Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status BIRC5 (survivin) : a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort The presence of an in situ component on pre-treatment biopsy is not associated with response to neoadjuvant chemotherapy for breast cancer Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer Interaction between molecular subtypes, stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS129.

Texte intégral

Résumé :

La chimiothérapie néoadjuvante (CNA) est utilisée dans les cancers du sein agressifs ou localement avancés (CS). Au delà des bénéfices cliniques, elle représente une opportunité pour monitorer in vivo la sensibilité d’une tumeur à un traitement.A partir de l’analyse de sets de données de patients traités par CNA, nous souhaitons identifier des mécanismes associes à la résistance ou sensibilité au traitement. Dans la première partie, nous avons évalué des paramètres, cliniques, anatomopathologiques et transcriptomiques. Nous avons démontré que des éléments non explorés comme la présence d’embol

Styles APA, Harvard, Vancouver, ISO, etc.

24

Chen, Yu-Hsiang. "Multi-Modality Plasma-Based Detection of Minimal Residual Disease in Triple-Negative Breast Cancer." Diss., 2019. http://hdl.handle.net/1805/20202.

Texte intégral

Résumé :

Indiana University-Purdue University Indianapolis (IUPUI)<br>Triple-negative breast cancers (TNBCs) are pathologically defined by the absence of estrogen, progesterone, and HER2 receptors. Compared to other breast cancers, TNBC has a relatively high mortality. In addition, TNBC patients are more likely to relapse in the first few years after treatment, and experiencing a shorter median time from recurrence to death. Detecting the presence of tumor in patients who are technically “disease-free” after neoadjuvant chemotherapy and surgery as early as possible might be able to predict recurr

Styles APA, Harvard, Vancouver, ISO, etc.

25

Bielčiková, Zuzana. "Cirkulující nádorové buňky u pacientek s karcinomem prsu." Doctoral thesis, 2017. http://www.nusl.cz/ntk/nusl-370957.

Texte intégral

Résumé :

Circulating tumor cells (CTCs) represent a systemic phase of the localised cancer disease. They can be distinguished and enriched from the peripheral blood and so from the surrounding leukocytes by either physical properties (e.g., density and size) or biological properties (e.g., expression of epithelial proteins such as EpCAM or cytokeratins) and are usually further characterized by immunostaining or RT-PCR assays. Selecting patients with the risk of disease relaps at the time of diagnosis is crucial for clinicians in deciding who should, and who should not, receive adjuvant chemotherapy. We

Styles APA, Harvard, Vancouver, ISO, etc.

26

Kramarzová, Karolina. "Role genu WT1 a jeho izoforem v hematopoeze a leukemogenezi." Doctoral thesis, 2013. http://www.nusl.cz/ntk/nusl-321451.

Texte intégral

Résumé :

61 Summary Wilms' tumor gene 1 (WT1) is highly expressed in acute leukemia and other hematological malignancies. It has been therefore suggested as a potential universal marker of minimal residual disease (MRD), particularly in patients with acute myeloid leukemia (AML). Due to controversial results of some of the studies, the role of WT1 in MRD follow-up and WT1 prognostic significance remain unclear. WT1 protein is produced in more than 36 different isoforms. These variants have distinct, partially overlapping functions and their ratio is supposed to influence the final effect of WT1. Howeve

Styles APA, Harvard, Vancouver, ISO, etc.

27

Richter, Daniel. "Treatment planning for tumors with residual motion in scanned ion beam therapy." Phd thesis, 2012. https://tuprints.ulb.tu-darmstadt.de/3071/1/thesis_dr_2012_09_05_pubweb.pdf.

Texte intégral

Résumé :

The treatment of mobile tumors with a scanned ion beam requires dedicated beam delivery and treatment planning techniques. Interference effects (interplay) between beam and tumor motion can lead to clinically unacceptable dose distributions. Motion mitigation techniques, such as beam gating or irradiation under abdominal compression, can effectively reduce tumor motion but typically do not fully compensate motion-induced dose inhomogeneities. Further mitigation therefore is desirable. In this work, the dosimetric impact of optimized treatment plan parameters on dose heterogeneities caused

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!